3 distinct publishers, one article each in this sample.
Ownership mix: Other: 3
3 publishers · 3 articles · switch to 1-minute for disagreement and framing.
Summit’s ivonescimab was seen as a test case for whether the country’s medicine could pass scrutiny in the US
AI-assisted comparison · labeled · generated Nov 15, 2026, 12:58 PM · not a verdict
This story is currently covered by only 1 source. Comparison requires at least two sources from different bias positions.
AI-assisted · Cerebras / Llama · Nov 15, 2026, 12:58 PM · inspect sources below rather than trusting this alone
This story is currently covered by only 1 source. Comparison requires at least two sources from different bias positions.
Oldest → newest among clustered members. Gaps may mean delayed pickup, not silence.
Perspective labels are external consensus ratings (AllSides / Ad Fontes / MBFC-style), not WeSearch truth scores. Center is not automatically more accurate.
Vocabulary fingerprints · not a political endorsement
Both outlets report the FDA's rejection of a Chinese-developed lung cancer drug. The Financial Times highlights the economic impact on Beijing's biotech sector, using the term 'blow' to denote the severity of the setback. The New York Times focuses on the procedural aspect, describing the drug as 'closely watched' to underscore the intensity of regulatory and public attention on the decision.
Bias/ownership: published methodology on source profiles · AI text always labeled · no reader paywall · no engagement ranking of news · transparency · contribute Ws · home